Key facts
- This page summarizes Stephane Bancel's Form 4 filing for Moderna, Inc. (MRNA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 May 2022, 16:07.
Stephane Bancel - 16 May 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- MRNA
- Reported as of
- 16 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 May 2022, 16:07:10 UTC
- Prior SEC filing
- 13 May 2022
- Next SEC filing
- 20 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Sandstrom, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephane Bancel filed Form 4 for Moderna, Inc. (MRNA) on 18 May 2022.
Change
- Previous filing in this sequence was filed on 13 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNA
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- +24,411
- Change %
- +0.45%
- Price
- $0.000000
- Shares after
- 5,415,946
- Date
- 16 May 2022
- Ownership
- Direct
- Footnotes
- F1
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 9,050,372
- Date
- 16 May 2022
- Ownership
- See Footnote
- Footnotes
- F2
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,894,880
- Date
- 16 May 2022
- Ownership
- See Footnote
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents the receipt of shares by the reporting person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") to the partners of Flagship Fund IV and by its general partner, Flagship Ventures Fund IV General Partner, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
Footnote F2
These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
Footnote F3
These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.